Acute Toxicity Evaluation of the new Benzimidazole derivative 3-[2-(2-Amino-1H-benzimidazol-1-yl)ethyl]-1,3-oxazolidin-2-one on the Wistar Rat

This work aims to determine the toxicological profile of a new Benzimidazole derivative in the Wistar rat by determining its acute toxicity. The molecule studied; 3-[2-(2-Amino-1H-benzimidazol-1-yl)ethyl]-1,3-oxazolidin-2-one (OXB₂) was synthesized in our laboratory and then characterized by several physicochemical techniques. Different doses of OXB₂ (500, 600, 700, 800 and 1000 mg/kg) were injected intraperitoneally into five groups of rats in addition to a control group which received only the vehicle solution, and then they were followed daily for 14 days. Food and water consumption, body weight, behavioral changes and mortalities were monitored during this period and the lethal dose 50 (LD₅₀) of this molecule was 854 mg/kg. The molecule studied did not impact food intake or water consumption, body weight or viability of rats administered at a dose of 600 mg/kg. Organ weights were also not affected at this dose and levels of hematological and biochemical values were not affected. The no observed adverse effect level (NOAEL) of OXB2 in Wistar rats confirms this dose. These results suggest that upon further analysis, OXB₂ could potentially be tested in preliminary clinical trials.